FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number: 3235-0287									
Estimated average burden									
hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Robinson James A. Jr.						2. Issuer Name and Ticker or Trading Symbol UroGen Pharma Ltd. [URGN]						(Che	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner			
(Last)	(F	irst)				3. Date of Earliest Transaction (Month/Day/Year) 08/06/2024							Officer below)	(give title	Other (s below)	pecify
400 ALEXANDER PARK DRIVE				4. 1	4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable Line)				
(Street) PRINCE	TON N	J	08540											led by More t	Reporting Personthan One Report	
(City) (State) (Zip)					Rı	Rule 10b5-1(c) Transaction Indication										
						Check	k this box t y the affirm	to indic	cate that a trar defense condi	saction was n tions of Rule 1	nade pursua 0b5-1(c). Se	nt to a contr ee Instructio	act, instructio n 10.	n or written pla	an that is intended	I to
		Tab	le I - Nor	n-Deriv	vative	e Sec	curities	Aco	quired, Di	sposed o	of, or Be	neficiall	y Owned			
1. Title of Security (Instr. 3) 2. Transar Date (Month/Date)						ar) E	2A. Deemed Execution Date, f any (Month/Day/Year)		Transaction Disposed Of (D Code (Instr. 5)		ecurities Acquired (A) or posed Of (D) (Instr. 3, 4 and ount (A) or Price			s Fally (I	orm: Direct D) or Indirect I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership Instr. 4)
								Code V	Amount	Reported Transact (Instr. 3 a			ion(s)			
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Dat if any (Month/Day/Ye	Date,	Code (5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option (right ot buy)	\$15.16	08/06/2024			A		10,000		(1)	08/06/2034	Ordinary Shares	10,000	\$0	10,000	D	

Explanation of Responses:

1. The shares underlying the stock option will vest in equal quarterly installments over a period of one year, subject to the director's Continuous Service (as defined in the 2017 Equity Incentive Plan) through such vesting dates.

/s/ Jason D. Smith, Attorney-

** Signature of Reporting Person

08/07/2024

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.